Human Antibodies & Hybridomas

7-9 November 2012, Buena Vista Palace Hotel, Orlando, Florida, USA

  • Increase font size
  • Default font size
  • Decrease font size

Day Two

Final Conference Programme | Thursday 8th November

SESSION 5:
MOLECULAR BIOLOGY

Moderator: David Humphreys (UCB Pharma, Slough, Berkshire, UK)

09.00-09.30
‘Engineering mouse immune loci to generate novel antibody-like molecules’
Lynn Macdonald (Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA)

09.30-09.50
‘Ylanthia – A novel library concept for the generation of antibody drug candidates’
Stefanie Urlinger (Morphosys AG, Martinsried, Germany)

09.50-10.10
‘Genetic immunization, an alternative for generating therapeutic antibodies’
Thomas W. Lynch (Aldevron, Madison, Wisconsin, USA)

10.10-10.30
‘The OMT antibody platform: Fully human antibodies from transgenic rats’
Roland Buelow (OMT Inc., Palo Alto, California, USA)

10.30-11.00
Coffee Break

SESSION 6:
INFECTIOUS DISEASES II

Moderator: Miroslaw K. Gorny (New York University, New York, USA)

11.00-11.30
‘Improved antibody therapies for the treatment of Clostridium difficile infection’
David Humphreys (UCB Pharma, Slough, Berkshire, UK)

11.30-11.50
‘An effective approach for the generation and characterization of neutralizing monoclonal antibodies to viral targets’
Nancy Chan, Lena Kikuchi, Adam Feire, Peter LeMotte and Chonghui Zhang (Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, USA)

11.50-12.10
‘An endogenous human antibody against a conserved M2 epitope confers full protection against influenza A strains’
Roger Beerli (Intercell AG, Schlieren, Switzerland)

12.10-12.30
‘Immunogenic mechanisms driving norovirus G11.4 antigenic variation’
Lisa Lindesmith (University of North Carolina, Chapel Hill, North Carolina, USA)

12.30-12.50
‘Development of catalytic human antibody light chains (antigenases) showing suppression of rabies virus infection’
Taizo Uda, Akira Nishizono and Emi Hifumi (Oita University, Oita-shi, Japan)

12.50-14.00
Lunch Break

SESSION 7:
CANCER II

Moderator: Jean-Luc Teillaud (INSERM / Cordeliers Research Center, Paris, France)

14.00-14.30
‘Development of monoclonal antibody based cancer therapeutics targeting B7-H3’
Paul Moore (Macrogenics Inc., Rockville, Maryland, USA)

14.30-14.50
‘Recruiting T cells to destroy tumors: a tetravalent bispecific anti-CD19 x anti-CD3 TandAb designed for the treatment of hematological malignancies’
Eugene Zhukovsky (Affimed Therapeutics AG , Heidelberg, Germany)

14.50-15.10
‘Human antibody light chains (antigenases) showing cytotoxicity against cancer cells’
Emi Hifumi and Taizo Uda (Oita University, Oita-shi, Japan)

15.10-15.40
Tea Break

SESSION 8A:
Special Presentation

Moderator: Mark C. Glassy (IMSA Foundation/Nascent Biologics Inc., San Diego, California, USA)

15.40-16.10
‘Virtual microscopy: The next paradigm shift in pathology and how it applies to immunohistochemistry stains’
Eric F. Glassy (Affiliated Pathologists Medical Group, Torrance, California, USA)

SESSION 8B:
Special Presentation

Moderator: Mark C. Glassy (IMSA Foundation/Nascent Biologics Inc., San Diego, California, USA)

16.10-16.40
‘Monoclonal antibody patents: Evolving law & strategies’
Andrew Serafini (Fenwick & West LLP, Seattle, Washington, USA)

Free Evening for Delegates

 

HAH 2012 Delegates

Login details will be supplied after you have registered for the event.


HAH 2012 Sponsors

  • UCB Celltech
  • Immunome
  • Morphosys
  • Mapp Biopharmaceutical
  • Retroscreen Virology
  • Nascent Biologics
  • Kenta Biotech
  • Geneuro
  • Novartis Vaccines
  • ImmunoGen
  • Adimab
  • Catalent
  • Regeneron
  • Becton Dickinson
  • Kadmon
  • Theraclone Sciences
  • Arsanis Biosciences
  • ImClone Systems
  • GlaxoSmithKline
  • Genentech
  • Dyax
  • Affimed
  • OMT
  • Aldevron
  • Selexis
  • Morphotek
  • Intercell
  • Fenwick & West
  • CytomX Therapeutics
  • Symphogen
  • ModiQuest
  • Fusion Antibodies

HAH 2012 Downloads

HAH 2012 Leaflet

HAH 2012 Mailing List

Name
E-mail Address
What is 1+4-2?